PROFUSA, INC. Deferred Offering Costs
PROFUSA, INC. (PFSA) had Deferred Offering Costs of $2.50 million as of 2025-12-31, per its S-1/A filed 2026-05-01.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-05-01
- 2025-12-31: Deferred Offering Costs $2.50M.
- 2025-09-30: Deferred Offering Costs $0.00.
- 2024-12-31: Deferred Offering Costs $2.80M.
- 2023-09-30: Deferred Offering Costs $679.62K.
| Period end | Deferred Offering Costs |
|---|---|
| 2025-12-31 | $2.50M S-1/A · filed 2026-05-01 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-19 |
| 2024-12-31 | $2.80M 10-Q · filed 2025-11-19 |
| 2023-09-30 | $679.62K 10-Q · filed 2023-11-20 |
| 2023-06-30 | $679.62K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $679.62K 10-Q · filed 2023-05-17 |
| 2022-12-31 | $258.55K 10-K · filed 2023-03-06 |
| 2022-09-30 | $258.55K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $258.55K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $258.55K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $258.55K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |